Email updates

Keep up to date with the latest news and content from Lipids in Health and Disease and BioMed Central.

Open Access Research

The effects of time-released garlic powder tablets on multifunctional cardiovascular risk in patients with coronary artery disease

Igor A Sobenin13*, Valentin V Pryanishnikov1, Lyudmila M Kunnova2, Yevgeny A Rabinovich2, Danik M Martirosyan4 and Alexander N Orekhov13

Author Affiliations

1 Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Moscow 125315, Russia

2 Moscow Municipal Cardiology Health Center, Moscow 121552, Russia

3 Institute for Atherosclerosis Research, Moscow 121609, Russia

4 Functional Food Center Inc., Richardson, TX 75080, USA

For all author emails, please log on.

Lipids in Health and Disease 2010, 9:119  doi:10.1186/1476-511X-9-119

Published: 19 October 2010

Abstract

The double-blinded placebo-controlled randomized study has been performed in 51 coronary heart disease (CHD) patients to estimate the effects of time-released garlic powder tablets Allicor on the values of 10-year prognostic risk of acute myocardial infarction (fatal and non-fatal) and sudden death, with the respect of secondary CHD prevention. It has been demonstrated that 12-month treatment with Allicor results in the significant decrease of cardiovascular risk by 1.5-fold in men (p < 0.05), and by 1.3-fold in women. The above results were equitable also in terms of relative risks. The main effect that played a role in cardiovascular risk reduction was the decrease in LDL cholesterol by 32.9 mg/dl in men (p < 0.05), and by 27.3 mg/dl in women. Thus, the most significant effects were observed in men, while in women the decrease of cardiovascular risk appeared as a trend that might be due presumably to the insufficient sample size. Since Allicor is the remedy of natural origin, it is safe with the respect to adverse effects and allows even perpetual administration that may be crucial for the secondary prevention of atherosclerotic diseases in CHD patients.